Recombinant Human Insulin
1,671 adverse event reports submitted to the FDA
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
1,671
Total Reports
75
Deaths Reported
450.0%
Death Rate
Active Ingredients
Recombinant Human Insulin
Administration Routes
SubcutaneousUnknownIntradermalCutaneousOphthalmicOral
Species Affected
Dog 1,021
Cat 471
Unknown 172
Human 7
Most Affected Breeds
Crossbred Canine/dog 307
Domestic Shorthair 286
Unknown 181
Retriever - Labrador 136
Cat (unknown) 65
Schnauzer - Miniature 61
Pug 60
Dachshund (unspecified) 52
Domestic Longhair 49
Pinscher - Miniature 40
Most Reported Reactions
Vomiting 223
Lack of efficacy - NOS 182
Lethargy (see also Central nervous system depression in 'Neurological') 176
INEFFECTIVE, GLYCEMIC CONTROL 159
Hypoglycaemia 158
Decreased appetite 98
Uncoded sign 88
Suspension, Abnormal 70
Cataract 69
Diarrhoea 68
Urinary tract infection 66
Product problem 61
Outcome Breakdown
Recovered/Normal
866 (57.5%)
Outcome Unknown
445 (29.6%)
Ongoing
107 (7.1%)
Euthanized
52 (3.5%)
Died
23 (1.5%)
Recovered with Sequela
12 (0.8%)
Source: FDA Center for Veterinary Medicine — Adverse Event Reports. Data reflects voluntary submissions and may not represent actual incidence rates.